WASHINGTON, D.C. (April 22, 2021) — The Association for Accessible Medicines (AAM), representing manufacturers of reliable, low-cost generic drugs, is disappointed that the Oregon State Senate voted to pass a measure that will increase the cost of prescription drugs for Oregonians.
Patent settlements have taken years off the monopoly protections that some of the most expensive brand name drugs have enjoyed and allowed generic and biosimilar competitors to lower costs for patients. SB 764 would prevent patent settlements that help consumers. The bill will delay access to affordable, effective, FDA-approved generics and biosimilar medicines.
AAM will continue to engage in productive conversations with the Legislature and stakeholders to illustrate the harmful impact of this bill with the goal of increasing access to lower-cost prescription drugs for Oregon's patients.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.